SALT LAKE CITY, Utah – August 1, 2023 – Foldax®, Inc., a leader in the development of innovative, polymer heart valves, today announced that the first 30 patients have been treated outside of the U.S. in the Indian clinical trial of the TRIATM surgical mitral heart valve. The TRIA mitral valve is designed specifically to accommodate the anatomy and pressures of the mitral posion. It combines the company’s proprietary polymer – LifePolymerTM – with an innovative valve design intended to resist calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants.
Rheumatic fever attacks the mitral valves and causes it to not close properly and leak. Developing countries have higher rates of rheumatic fever and, consequently, higher rates of mitral valve disease. It is estimated that two to three million people have rheumatic heart disease in India alone.